source
- AI-focused biotech firms drive biopharma toward a 'fail-fast' drug development modelAI is quickly becoming a central force in drug development as tech capital pours into biopharma, reshaping how new medicines are discovered. Tyrone Lam, chief business officer at GATC Health, says…
- Eli Lilly fronts $2 billion for vaccine biotech deals as Infinimmune secures $75 million fundingEli Lilly announced it has paid $2 billion up front as part of its ongoing strategy to acquire vaccine‑focused biotechnology companies, a portion of a larger deal that could total up to $3.8 billio…